Earlier last week, the company obtained a go-ahead from the National Company Law Tribunal (NCLT) for the listing of its equity shares. Furt...

Last Thursday, the company said it has received Sebi’s go-ahead to list its equity shares on domestic stock exchanges

Piramal Enterprises Ltd., incorporated in the year 1947, is a Large Cap company (having a market cap of Rs 25383.08 Crore) operating in Div...

The record date for the demerger of the pharma business from the finance business has been set as September 1 and stock traded ex-demerger ...

Piramal Enterprises has secured the approval of the National Company Law Tribunal (NCLT) for the demerger of its pharmaceutical business an...

“I would think that Reliance could languish for some more time and I do not think any demerger is going to happen fast. The new generation ...

Ajay Piramal, chairperson of PEL said the company is on track to achieve the completion of demerger and separate listing of PPL by the thir...

The non-banking finance company incurred an exceptional cost of Rs 153 crore, which is primarily on account of DHFL. Without this, the net ...

The amalgamation of PHL Fininvest Private Limited with PEL will create a listed non-banking financial services (NBFC) entity. The merged ho...

The pharmaceuticals business will get vertically demerged from Piramal Enterprises and consolidated under Piramal Pharma Ltd (PPL), the gro...

The pharmaceuticals business will get demerged from Piramal Enterprises (PEL) and consolidated in Piramal Pharma, Piramal Enterprises said ...

The company made its stand clear through a communication to exchanges.

Piramal Enterprises is growing largely organically with a CAGR of 17 per cent over last the five years.

The Piramal Group, which was primarily a pharmaceutical business, has diversified into areas such as finance, private and real estate fundi...

Ajay Piramal-led Piramal Enterprises is looking to demerge its healthcare and financial services businesses to grow unrelated divisions sep...

Diversified company Piramal Enterprises today reported a consolidated net profit of Rs 4.08 crore for the quarter ended June 30, 2012.

Emkay Global Financial Services has initiated ‘buy’ on Piramal Life Sciences for a target price of Rs 270.